BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

A study of nearly 540,000 COVID-19 cases by Oxford University found that about 4 in 1 million people experience cerebral venous thrombosis (brain blood clots) after receiving the Pfizer vaccine ...

Researchers looked at how the vaccine affected patients' corneas - the clear front part of the eye that allows light to come ...

According to Pfizer, "Hundreds of millions of doses of the Pfizer-BioNTech COVID-19 vaccine have been administered globally, and the benefit-risk profile of the vaccine remains positive for all ...

New data from Pfizer were also made public on Friday. They show that the vaccine is about 91% effective in preventing Covid-19 in 5- to 11-year-olds. “While benefits of vaccination were highly ...

Scientists in Turkey found that the Pfizer COVID-19 vaccine impacted some people's corneas, according to a study.

A federal advisory committee is evaluating Pfizer's COVID-19 vaccine. The Food and Drug Administration will weigh that input as it decides whether to grant emergency use for the vaccine.

FDA says Pfizer Covid vaccine benefits outweigh risks for kids ages 5 to 11 Agency reviewers stopped short of calling for Pfizer’s shot to be authorized. The agency will put that question to a ...

The analysis came on the same day that the Food and Drug Administration posted data from Pfizer showing that the vaccine had a 90.7 percent efficacy rate in preventing symptomatic Covid-19 in a ...

An FDA review states that the benefits of Pfizer’s COVID-19 vaccine in kids ages 5 to 11 outweigh the potential risks, The Washington Post reported. The FDA noted in its review, released Oct. 22 ...

Scientists at the U.S. Food and Drug Administration (FDA) said on Friday that the likely benefits of giving the Pfizer /BioNTech COVID-19 vaccine to 5 to 11 year olds clearly outweigh the risks of ...

A study released Friday found that kid-size doses of Pfizer’s COVID-19 vaccine are nearly 91 percent effective at preventing symptomatic infections in 5- to 11-year-olds.